News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (329 of 379). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (14 of 379). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (36 of 379). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 277 of 379 items have one.
Improving early detection of cognitive impairment in primary care
Early detection of cognitive impairment can connect patients with evaluation and treatment sooner, but many screening methods are difficult to incorporate into routine primary care. …
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveResearchers explore new diagnostic tools, genetic roots for early-onset dementia
Researchers at the new Center for Brain Health at UT Health San Antonio are studying midlife testing for early-onset dementia with blood-based biomarkers to see if they can detect disease activity up to 20 years before symptoms appear.
Why it matters: Midlife blood-based biomarker testing is being studied to see if it can detect early-onset dementia activity up to 20 years before symptoms appear.
Read at Medical Xpress → Archived copy (27 Jan 2026), Internet ArchiveStudy finds ongoing under-diagnosis of high blood pressure in people over 50 in Ireland
High blood pressure becomes more common after age 40, yet new research from The Irish Longitudinal Study on Ageing (TILDA) at Trinity College Dublin shows that many people in Ireland with hypertension are still not optimally diagnosed or treated based on European Guidelines. …
Why it matters: New research shows many people over 50 in Ireland with high blood pressure are still not optimally diagnosed or treated based on European Guidelines.
Read at Medical Xpress → Archived copy (4 Feb 2026), Internet ArchiveA hidden brain signal may reveal Alzheimer’s long before diagnosis
Researchers have discovered a brain activity pattern that can predict which people with mild cognitive impairment are likely to develop Alzheimer’s disease. …
Read at ScienceDaily → Archived copy (18 Sep 2026), Internet ArchiveNew AI technology can provide rapid and reliable dementia diagnosis
Researchers at Örebro University have developed two new AI models that can analyze the brain's electrical activity and accurately distinguish between healthy individuals and patients with dementia, including Alzheimer's disease.
Why it matters: Researchers developed AI models analyzing brain electrical activity to distinguish healthy individuals from dementia and Alzheimer's patients.
FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease
The FDA granted 510(k) clearance to Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first blood test cleared to help diagnose Alzheimer's in adults 55 and older with signs of cognitive decline. In FDA's review, positive results correctly identified amyloid plaques 91.7% of the time and negative results correctly ruled them out 97.3% of the time.
Why it matters: A simple blood draw can now help identify amyloid plaques without a spinal tap or PET scan, potentially speeding diagnosis and lowering costs, though FDA stressed it isn't a stand-alone diagnostic test.
Read at FDA → Archived copy (10 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.